Mink Therapeutics Inc (INKT) Stock Price, Quote & News

Latest News on INKT

Mar 4, 2025, 7:30 AM EST - 9 days ago

MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Feb 24, 2025, 8:30 AM EST - 17 days ago

MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting

Feb 12, 2025, 1:00 PM EST - 4 weeks ago

MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting

Jan 23, 2025, 2:13 PM EST - 7 weeks ago

MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI

Dec 18, 2024, 9:45 AM EST - 3 months ago

MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting

Nov 14, 2024, 10:47 AM EST - 4 months ago

MiNK Therapeutics, Inc. (INKT) Q3 2024 Earnings Conference Call Transcript

Nov 11, 2024, 7:30 AM EST - 4 months ago

MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report

Nov 7, 2024, 10:00 AM EST - 4 months ago

MiNK's iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024

Oct 31, 2024, 9:15 AM EDT - 4 months ago

MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors

Oct 8, 2024, 7:30 AM EDT - 5 months ago

MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors

Oct 4, 2024, 9:10 AM EDT - 5 months ago

MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024

Sep 3, 2024, 7:30 AM EDT - 6 months ago

MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference

Aug 13, 2024, 2:51 PM EDT - 7 months ago

MiNK Therapeutics, Inc. (INKT) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 7:00 AM EDT - 7 months ago

MiNK Reports Second Quarter 2024 Results and Business Update

Aug 1, 2024, 7:30 AM EDT - 8 months ago

MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report

Jul 31, 2024, 7:30 AM EDT - 8 months ago

MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement

Jun 5, 2024, 7:30 AM EDT - 10 months ago

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

May 22, 2024, 7:30 AM EDT - 10 months ago

MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting

May 14, 2024, 11:07 AM EDT - 10 months ago

MiNK Therapeutics, Inc. (INKT) Q1 2024 Earnings Call Transcript

May 14, 2024, 7:30 AM EDT - 10 months ago

MiNK Reports First Quarter 2024 Results

May 13, 2024, 7:30 AM EDT - 10 months ago

MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer

Apr 30, 2024, 7:30 AM EDT - 11 months ago

MiNK to Provide Corporate Update and First Quarter 2024 Financial Report

Apr 8, 2024, 12:00 PM EDT - 1 year ago

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

Mar 21, 2024, 2:20 PM EDT - 1 year ago

MiNK Therapeutics, Inc. (INKT) Q4 2023 Earnings Call Transcript

Mar 21, 2024, 7:00 AM EDT - 1 year ago

MiNK Reports Fourth Quarter and Year-End 2023 Results

Mar 7, 2024, 7:30 AM EST - 1 year ago

MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

Mar 6, 2024, 8:30 AM EST - 1 year ago

MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024

$MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene$

Jan 30, 2024, 8:00 AM EST - 1 year ago

MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

Dec 20, 2023, 7:30 AM EST - 1 year ago

ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development

Nov 9, 2023, 7:00 AM EST - 1 year ago

MiNK Therapeutics Reports Third Quarter 2023 Results

Nov 3, 2023, 12:00 PM EDT - 1 year ago

MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023

Oct 30, 2023, 8:00 AM EDT - 1 year ago

MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update

Sep 27, 2023, 9:05 AM EDT - 1 year ago

MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023

Aug 24, 2023, 8:30 AM EDT - 1 year ago

MiNK Therapeutics to Participate in September Investor Conferences

Aug 10, 2023, 7:30 AM EDT - 1 year ago

MiNK Therapeutics Reports Second Quarter 2023 Results

Jul 28, 2023, 8:30 AM EDT - 1 year ago

MiNK to Provide Second Quarter 2023 Financial Report and Corporate Update

May 22, 2023, 8:30 AM EDT - 1 year ago

MiNK Presents Clinical Data on Allogeneic iNKT Cells (agenT-797) in Severe Respiratory Distress at the American Thoracic Society International Conference

May 18, 2023, 8:30 AM EDT - 1 year ago

MiNK's Novel FAP-CAR-iNKT Presented at ASGCT

May 14, 2023, 2:25 PM EDT - 1 year ago

MiNK Therapeutics, Inc. (INKT) Q1 2023 Earnings Call Transcript

May 11, 2023, 8:00 AM EDT - 2 years ago

MiNK Therapeutics Reports Corporate Update and First Quarter 2023 Financial Results

Apr 27, 2023, 8:30 AM EDT - 2 years ago

MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results

Apr 18, 2023, 1:32 PM EDT - 2 years ago

MiNK Therapeutics Announces Clinical Data of Allogeneic iNKT Cells (agenT-797) in Solid Tumor Cancers at the AACR Annual Meeting

Mar 25, 2023, 2:17 AM EDT - 2 years ago

MiNK Therapeutics: iNKT Therapy Data Should Drive Stock Price Up

Mar 21, 2023, 12:26 PM EDT - 2 years ago

MiNK Therapeutics, Inc. (INKT) Q4 2022 Earnings Call Transcript

Mar 21, 2023, 8:00 AM EDT - 2 years ago

MiNK Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Mar 15, 2023, 8:45 AM EDT - 2 years ago

MiNK Therapeutics to Present Updated Clinical Data of allo-iNKT Cell Therapy in Solid Tumors at AACR Annual Meeting

Mar 7, 2023, 9:00 AM EST - 2 years ago

MiNK Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results

Feb 16, 2023, 9:28 AM EST - 2 years ago

MiNK Therapeutics to Participate in HC Wainwright Cell Therapy Virtual Conference

Jan 11, 2023, 2:25 PM EST - 2 years ago

MiNK Therapeutics to Participate in B. Riley Securities Oncology Conference

Dec 5, 2022, 10:43 PM EST - 2 years ago

Market Cap	32.50M
Revenue (ttm)	0.00
Net Income (ttm)	-22.46M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-0.26

Volume	4,800
Avg Vol	40,001
Day's Range	N/A - N/A
Shares Out	3.96M
Stochastic %K	33%
Beta	0.16
Analysts	Strong Sell
Price Target	$37.50